DMT:CC News and Press, Small Pharma Inc. From 10/02/23

LONDON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Mr. Peter Rands disposed of an aggregate of 1,532,001 common shares in the capital of Small Pharma Inc. (the “ Company ”) between September 25, 2023 and September 27, 2023 at an average price of $0.177 per common share for aggregate proc...

• Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable dose of SSRIs versus patients not on SSRIs • At Week 4, 100% of patients in the SSRI cohort responded to SPL026 (DMT) with 92% of patients in remission from depres...

2023-08-31 20:00:00 ET Small Pharma Inc is among the group of undervalued stocks on the TSX Venture Exchange. This means the consensus value for each stock on this list is above its current price. This report is generated monthly. It provides the close price and target price for these...

Canadian Investment Regulatory Organization Trade Resumption - DMT Canada NewsWire VANCOUVER, BC , Aug. 28, 2023 /CNW/ - Trading resumes in: Company: Small Pharma Inc. TSX-Venture Symbol: DMT All Issues: Yes Resumption (ET): 11:05 AM CIRO can ...

- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics - - Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy - - Combined portfolio creates the indust...

Canadian Investment Regulatory Organization Trading Halt - DMT Canada NewsWire VANCOUVER, BC , Aug. 28, 2023 /CNW/ - The following issues have been halted by CIRO Company: Small Pharma Inc. TSX-Venture Symbol: DMT All Issues: Yes Reason: P...

• Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023 • Potential for an expedited route to an international, multi-site Phase II study with SPL028 in 2024, based on clinical findings across SPL026 and SPL028 programs to date ...

• Preliminary findings from ongoing Phase I trial of second-generation DMT asset SPL028 indicate the potential for a unique therapeutic profile • Proof-of-concept data from Company’s native DMT program, SPL026, offers potential for an expedited rou...

LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that Mr. P...

• Multiple clinical milestones achieved including the first proof-of-concept for DMT-based therapies from a blinded placebo-controlled study • Preliminary findings from SPL028 Phase I clinical trial support target drug profile • Operational efficiencies unde...